| Literature DB >> 32030428 |
Tetsuya Ohira1,2, Hiroki Shimura1,3, Fumikazu Hayashi1,2, Masanori Nagao1,2, Seiji Yasumura1,4, Hideto Takahashi1,5, Satoru Suzuki1, Takashi Matsuzuka1,6, Satoshi Suzuki1,7, Manabu Iwadate1,7, Tetsuo Ishikawa1,8, Akira Sakai1,9, Shinichi Suzuki1,7, Kenneth E Nollet1,10, Susumu Yokoya1,11, Hitoshi Ohto1, Kenji Kamiya1,12.
Abstract
The identification of thyroid cancers among children after the Chernobyl nuclear power plant accident propelled concerns regarding long-term radiation effects on thyroid cancer in children affected by the Fukushima Daiichi nuclear power plant accident in Fukushima, Japan. Herein we consider the potential association between absorbed dose in the thyroid and the risk of developing thyroid cancer as detected by ultrasonography on 300 473 children and adolescents aged 0-18 years in Fukushima. The absorbed dose mentioned in the present study indicates the sum of that from external exposure and that from internally deposited radionuclides. We grouped participants according to estimated absorbed doses in each of 59 municipalities in Fukushima Prefecture, based on The United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) 2013 report. The 59 municipalities were assigned to quartiles by dose. We limited our analyses to participants aged ≥6 years because only one case of thyroid cancer was observed in participants aged ≤5 years; 164 299 participants were included in the final analysis. Compared with the lowest dose quartile, the age- and sex-adjusted rate ratios (95% confidence intervals) for the low-middle, high-middle and highest quartiles were 2.00 (0.84-4.80), 1.34 (0.50-3.59) and 1.42 (0.55-3.67) for the 6-14-year-old groups and 1.99 (0.70-5.70), 0.54 (0.13-2.31) and 0.51 (0.12-2.15) for the >15-year-old group, respectively. No dose-dependent pattern emerged from the geographical distribution of absorbed doses by municipality, as estimated by UNSCEAR, and the detection of thyroid cancer among participants within 4-6 years after the accident. Ongoing surveillance might further clarify the effects of low-dose radiation exposure on thyroid cancer in Fukushima.Entities:
Mesh:
Year: 2020 PMID: 32030428 PMCID: PMC7246065 DOI: 10.1093/jrr/rrz104
Source DB: PubMed Journal: J Radiat Res ISSN: 0449-3060 Impact factor: 2.724
Fig. 1.Geographical distribution of the highest, high-middle, low-middle and lowest dose areas based on maximum estimates by UNSCEAR, stratified by age groups.
Fig. 2.Geographical distribution of the highest, high-middle, low-middle and lowest dose areas based on minimum estimates by UNSCEAR, stratified by age groups.
Median (interquartile range), characteristics of participants and adjusted RRs (95% CIs) for thyroid cancer according to maximum absorbed doses in thyroid glands, as estimated by UNSCEAR
| Lowest quartile | Low middle | High middle | Highest quartile | Total | |
|---|---|---|---|---|---|
| Age 6–14 years | |||||
| Absorbed dose (mGy), range | 14.00–18.81 | 18.82–22.82 | 23.96–28.73 | 31.16–58.0 | |
| No. at risk | 35 175 | 44 555 | 33 387 | 32 390 | 145 507 |
| Sex (female), % | 49.2 | 49.5 | 49.1 | 49.7 | 49.4 |
| Age at NPP accident (years), median (25–75%) | 10 (8–12) | 10 (8–12) | 10 (8–12) | 10 (8–12) | 10 (8–12) |
| Age at baseline thyroid examination (years), median (25–75%) | 14 (12–16) | 14 (12–16) | 13 (11–16) | 14 (12–16) | 14 (12–16) |
| Participants needing confirmatory testing, | 341 (0.97) | 448 (1.01) | 328 (0.98) | 320 (0.99) | 1437 (0.99) |
| Participants completing confirmatory testing, | 271 (0.77) | 357 (0.80) | 273 (0.82) | 269 (0.83) | 1170 (0.80) |
| Participants getting FNAC, | 20 (7.4) | 45 (12.6) | 44 (16.1) | 31 (11.5) | 140 (12.0) |
| Examination year | |||||
| 2014 (%) | 7645 (21.7) | 38 370 (86.1) | 33 366 (99.9) | 8083 (25.0) | 87 464 (60.1) |
| 2015–17 (%) | 27 530 (78.3) | 6185 (13.9) | 21 (0.1) | 24 307 (75.0) | 58 043 (39.9) |
| Interval from baseline to follow-up examination (years), median (25–75%) | 2.0 (1.9–2.1) | 2.1 (2.0–2.2) | 2.1 (2.1–2.2) | 2.3 (2.1–2.6) | 2.1 (2.0–2.3) |
| No. of cases | 7 | 18 | 9 | 11 | 45 |
| Detection rate per 100 000 person-years | 10.1 | 19.2 | 12.5 | 14.7 | 14.5 |
| Age- and sex-adjusted RR (95% CI) | Ref. | 2.00 (0.84–4.80) | 1.34 (0.50–3.59) | 1.42 (0.55–3.67) | (Trend |
| Age-, sex- and examination year-adjusted RR (95% CI) | Ref. | 1.42 (0.52–3.86) | 0.90 (0.29–2.77) | 1.41 (0.55–3.64) | (Trend |
| Age ≥15 years | |||||
| Absorbed dose (mGy), range | 7.88–11.45 | 12.48–15.00 | 15.42–16.30 | 17.35–35.00 | |
| No. at risk | 4599 | 4827 | 4430 | 4936 | 18 792 |
| Sex (female), % | 57.9 | 55.5 | 56.7 | 56.2 | 56.6 |
| Age at NPP accident (years), median (25–75%) | 16 (15–17) | 16 (15–17) | 16 (15–17) | 16 (15–17) | 16 (15–17) |
| Age at baseline thyroid examination (years), median (25–75%) | 21 (20–22) | 20 (19–21) | 20 (19–21) | 21 (20–22) | 20 (19–21) |
| Participants needing confirmatory testing, | 125 (2.72) | 134 (2.78) | 109 (2.46) | 146 (2.96) | 514 (2.74) |
| Participants completing confirmatory testing, | 105 (2.28) | 113 (2.34) | 88 (1.99) | 114 (2.31) | 420 (2.23) |
| Participants getting FNAC, | 7 (6.7) | 18 (15.9) | 14 (15.9) | 7 (6.1) | 46 (11.0) |
| Examination year | |||||
| 2014 (%) | 1778 (38.7) | 4825 (99.96) | 4426 (99.9) | 1349 (27.3) | 12 378 (65.9) |
| 2015–17 (%) | 2821 (61.3) | 2 (0.04) | 4 (0.1) | 3587 (72.7) | 6414 (34.1) |
| Interval from baseline to follow-up examination (years), median (25–75%) | 2.1 (2.0–2.3) | 2.1 (2.0–2.6) | 2.1 (2.0–2.2) | 2.2 (2.0–2.6) | 2.1 (2.0–2.5) |
| No. of cases | 5 | 12 | 3 | 3 | 23 |
| Detection rate per 100 000 person-years | 51.0 | 108.2 | 30.9 | 26.6 | 54.9 |
| Age- and sex-adjusted RR (95% CI) | Ref. | 1.99 (0.70–5.70) | 0.54 (0.13–2.31) | 0.51 (0.12–2.15) | (Trend |
| Age-, sex- and examination year-adjusted RR (95% CI) | Ref. | 1.37 (0.43–4.34) | 0.38 (0.08–1.72) | 0.55 (0.13–2.33) | (Trend |
aParticipants who underwent FNAC/participants who completed confirmatory testing.
Median (interquartile range), characteristics of participants and adjusted RRs (95% CIs) for thyroid cancer according to minimum absorbed doses in thyroid glands, as estimated by UNSCEAR
| Lowest quartile | Low middle | High middle | Highest quartile | Total | |
|---|---|---|---|---|---|
| Age 6–14 years | |||||
| Absorbed dose (mGy), range | 12.00–18.81 | 18.82–22.61 | 22.82–28.73 | 29.00–58.00 | |
| No. at risk | 38 262 | 23 037 | 57 547 | 26 661 | 145 507 |
| Sex (female), % | 49.3 | 49.7 | 49.1 | 49.7 | 49.4 |
| Age at NPP accident (years), median (25–75%) | 10 (8–12) | 10 (8–12) | 10 (8–12) | 10 (8–12) | 10 (8–12) |
| Age at baseline thyroid examination (years), median (25–75%) | 14 (12–16) | 13 (11–16) | 14 (11–16) | 14 (12–16) | 14 (12–16) |
| Participants needing confirmatory testing, | 380 (0.99) | 251 (1.09) | 551 (0.96) | 255 (0.96) | 1,437 (0.99) |
| Participants completing confirmatory testing, | 302 (0.79) | 213 (0.92) | 444 (0.77) | 211 (0.79) | 1,170 (0.80) |
| Participants getting FNAC, | 25 (8.3) | 23 (10.8) | 69 (15.5) | 23 (10.9) | 140 (12.0) |
| Examination year | |||||
| 2014 (%) | 10 728 (28.0) | 16 876 (73.3) | 57 501 (99.9) | 2359 (8.8) | 87 464 (60.1) |
| 2015–17 (%) | 27 534 (72.0) | 6161 (26.7) | 46 (0.1) | 24 302 (91.2) | 58 043 (39.9) |
| Interval from baseline to follow-up examination (years), median (25–75%) | 2.0 (1.9–2.1) | 2.1 (2.0–2.4) | 2.1 (2.0–2.2) | 2.2 (2.1–2.5) | 2.1 (2.0–2.3) |
| No. of cases | 8 | 8 | 20 | 9 | 45 |
| Detection rate per 100 000 person-years | 10.4 | 15.9 | 16.4 | 14.8 | 14.5 |
| Age- and sex-adjusted RR (95% CI) | Ref. | 1.62 (0.61–4.32) | 1.68 (0.74–3.83) | 1.35 (0.52–3.50) | (Trend |
| Age-, sex- and examination year-adjusted RR (95% CI) | 1.22 (0.43–3.49) | 1.12 (0.43–2.95) | 1.60 (0.59–4.33) | (Trend | |
| Age ≥15 years | |||||
| Absorbed dose (mGy), range | 7.20–11.12 | 11.28–12.62 | 13.31–16.30 | 17.35–34.00 | |
| No. at risk | 4604 | 5160 | 4989 | 4039 | 18 792 |
| Sex (female), % | 58.1 | 54.8 | 57.2 | 56.3 | 56.6 |
| Age at NPP accident (years), median (25–75%) | 16 (15–17) | 16 (15–17) | 16 (15–17) | 16 (15–17) | 16 (15–17) |
| Age at baseline thyroid examination (years), median (25–75%) | 21 (20–22) | 20 (19–21) | 20 (19–21) | 21 (20–22) | 20 (19–21) |
| Participants needing confirmatory testing, | 124 (2.69) | 144 (2.79) | 128 (2.57) | 118 (2.92) | 514 (2.74) |
| Participants completing confirmatory testing, | 103 (2.24) | 120 (2.33) | 104 (2.08) | 93 (2.30) | 420 (2.23) |
| Participants getting FNAC, | 7 (6.8) | 23 (19.2) | 15 (14.4) | 1 (1.1) | 46 (11.0) |
| Examination year | |||||
| 2014 (%) | 1784 (38.7) | 5156 (99.9) | 4985 (99.9) | 453 (11.2) | 12 378 (65.9) |
| 2015–17 (%) | 2820 (61.3) | 4 (0.1) | 4 (0.1) | 3586 (88.8) | 6414 (34.1) |
| Interval from baseline to follow-up examination (years), median (25–75%) | 2.1 (2.0–2.4) | 2.1 (2.0–2.6) | 2.1 (2.0–2.3) | 2.1 (2.0–2.5) | 2.1 (2.0–2.5) |
| No. of cases | 5 | 13 | 4 | 1 | 23 |
| Detection rate per 100 000 person-years | 50.1 | 107.6 | 36.0 | 11.5 | 54.9 |
| Age- and sex-adjusted RR (95% CI) | Ref. | 2.03 (0.72–5.74) | 0.66 (0.17–2.51) | 0.23 (0.03–1.97) | (Trend |
| Age-, sex- and examination year-adjusted RR (95% CI) | 1.66 (0.47–5.86) | 0.54 (0.12–2.45) | 0.26 (0.03–2.42) | (Trend | |
aParticipants who underwent FNAC/participants who completed confirmatory testing.